Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Workman

Showing results (221-230 of 268) with videos related to

Pageof 27
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
European School of Oncology Task Force Report. New approaches in cancer pharmacology: drug design and development (Part 2)P Workman, M D'Incalci, W Bursch, et al.
Biochemical Pharmacology|October 23, 1998
Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: a detailed kinetic study and analysis of metabolitesS M Bailey, A D Lewis, R J Knox, et al.
Molecular Cancer Therapeutics|December 7, 2002
Inhibition of Kirsten-ras expression in human colorectal cancer using rationally selected Kirsten-ras antisense oligonucleotidesP J Ross, M George, D Cunningham, et al.
Analytical Biochemistry|October 25, 2001
High-throughput screening for identification of small molecule inhibitors of histone acetyltransferases using scintillating microplates (FlashPlate)F Turlais, A Hardcastle, M Rowlands, et al.
Biochemical Pharmacology|July 13, 2001
Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging speciesS M Bailey, A D Lewis, L H Patterson, et al.
Oncogene|August 30, 2000
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperoneP A Clarke, I Hostein, U Banerji, et al.
Anti-Cancer Drugs|June 1, 1994
Cyclopropamitosenes: novel bioreductive anticancer agents--mechanism of action and enzymic reductionC J Moody, N O'Sullivan, I J Stratford, et al.
International Journal of Cancer|October 1, 1994
Differential intracellular processing of the anthracycline drug ME2303 in doxorubicin-sensitive (A2780) and -resistant (A2780AD) human ovarian cancer cells as studied with confocal laser scanning microscopy and image analysisI M Huxham, A L Barlow, A D Lewis, et al.
British Journal of Cancer|December 1, 1996
In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022H L McLeod, V G Brunton, N Eckardt, et al.
British Journal of Cancer|January 1, 1997
Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9S M Bailey, M D Wyatt, F Friedlos, et al.
Pageof 27

Showing results (221-230 of 268) with videos related to

Sort By:
Pageof 27
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
European School of Oncology Task Force Report. New approaches in cancer pharmacology: drug design and development (Part 2)P Workman, M D'Incalci, W Bursch, et al.
Biochemical Pharmacology|October 23, 1998
Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: a detailed kinetic study and analysis of metabolitesS M Bailey, A D Lewis, R J Knox, et al.
Molecular Cancer Therapeutics|December 7, 2002
Inhibition of Kirsten-ras expression in human colorectal cancer using rationally selected Kirsten-ras antisense oligonucleotidesP J Ross, M George, D Cunningham, et al.
Analytical Biochemistry|October 25, 2001
High-throughput screening for identification of small molecule inhibitors of histone acetyltransferases using scintillating microplates (FlashPlate)F Turlais, A Hardcastle, M Rowlands, et al.
Biochemical Pharmacology|July 13, 2001
Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging speciesS M Bailey, A D Lewis, L H Patterson, et al.
Oncogene|August 30, 2000
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperoneP A Clarke, I Hostein, U Banerji, et al.
Anti-Cancer Drugs|June 1, 1994
Cyclopropamitosenes: novel bioreductive anticancer agents--mechanism of action and enzymic reductionC J Moody, N O'Sullivan, I J Stratford, et al.
International Journal of Cancer|October 1, 1994
Differential intracellular processing of the anthracycline drug ME2303 in doxorubicin-sensitive (A2780) and -resistant (A2780AD) human ovarian cancer cells as studied with confocal laser scanning microscopy and image analysisI M Huxham, A L Barlow, A D Lewis, et al.
British Journal of Cancer|December 1, 1996
In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022H L McLeod, V G Brunton, N Eckardt, et al.
British Journal of Cancer|January 1, 1997
Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9S M Bailey, M D Wyatt, F Friedlos, et al.
Pageof 27